IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Examiner: Shaw, Amanda Marie.
Joffre B. Baker, et al.	Art Unit: 1634
Application Serial No. 10/714,195	Confirmation No: 5745
Filed: November 14, 2003	Attorney's Docket No. 39740-0005A
For: **GENE EXPRESSION PROFILING OF EGFR POSITIVE CANCER**	**Customer No. 25213**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF JOFFRE B. BAKER, Ph.D UNDER 37 C.F.R. § 1.132

I, Joffre B. Baker, Ph.D. declare and say as follows:

1. I am the Chief Scientific Officer at Genomic Health, Inc., Redwood City, CA 94063.

2. I joined Genomic Health, Inc. in 2000 as the Chief Scientific Officer. My scientific Curriculum Vitae, including my list of publications, is attached to and forms part of this Declaration (Exhibit A).

3. During my employment with Genomic Health, Inc., I have been involved in supervising and analyzing gene expression profiling of EGFR positive colon cancer as described in Example 2 of the above-identified patent application.

4. I am aware that some of the claims in the above captioned patent application have been rejected under 35 U.S.C. § 112 as allegedly lacking enablement. My understanding is that the rejection is based, at least partially, on the assertion that it is unpredictable as to whether the

prognostic information obtained by the overexpression of LAMC2 and GCP3 in colon cancer cells is applicable to treatment with any EGFR inhibitor.

5. To the contrary however, it is my considered scientific opinion that Example 2 and Tables 3 and 4 are enabling and provide a strong basis for the determination that overexpression of LAMC2 and GPC3 RNA transcripts or their products in colon cancer cells is prognostic for the likelihood that a patient will or will not respond to treatment with any EGFR inhibitor.

6. In support of the conclusion made in paragraph 5 above, I offer the following evidence. As disclosed in Example 2 of the above captioned application, twenty three (23) colon adenocarcinoma patients were studied. mRNA was extracted from formalin-fixed colon tumor tissues from the patients and molecular assays of quantitative gene expression were performed by RT-PCR. After removal of the colon tumor tissue, the patients were treated with an EGFR inhibitor selected from the group, erlotinib, gefitinib, cytoximab, EMB72000, AEE788 and the patients were determined to have either a partial response, stable disease or progressive disease. The level of expression of mRNA transcripts in the colon tumors was correlated with either the partial response of the patients or the clinical benefit to the patients as described in Example 2. Table 3 of the above-captioned application shows the correlation of the gene expression with partial response of the patients. Table 4 of the above-captioned application shows the correlation of the gene expression with clinical benefit. Clinical benefit combines partial or complete response with stable disease (minimum 3 months).

7. Table 3 shows that overexpression of GPC3 in the colon tumor tissue showed a positive correlation with partial response to treatment with any of the EGFR inhibitors with a p value of 0.0097. Table 4 shows that overexpression of GPC3 in the colon tumor showed a positive correlation with clinical benefit to treatment with any of the EGFR inhibitors with a p value of 0.0025. Table 3 shows that overexpression of LAMC2 in the colon tumor tissue showed a negative correlation with partial response to treatment with any of the EGFR inhibitors with a p value of 0.0357. These results are statistically significant.

8. It necessarily follows from paragraph 7 that the overexpression of GPC3 in colon tumor tissue positively correlates with treatment with any EGFR inhibitor and therefore overexpression of GPC3 in colon tumor tissue indicates that the patient will show an increased likelihood of response to treatment with an EGFR inhibitor. Furthermore overexpression of LAMC2 in colon tumor tissue negatively correlates with treatment with any EGFR inhibitor and therefore overexpression of LAMC2 in colon tumor tissue indicates that the patient will show an decreased likelihood of response to treatment with any EGFR inhibitor.

9. Furthermore, the results presented in Example 2 and Tables 3 and 4 were the result of treatment with a variety of different EGFR inhibitors. Therefore the prognostic information obtained by overexpression of LAMC2 or GPC3 genes is applicable to treatment with the class of drugs called EGFR inhibitors which inhibit a biological function of a native EGFR.

10. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Signed: Joffre B. Baker

Joffre B. Baker, Ph.D.

Date: Dec 21, 2006

12/21/06 3:20 PM O

Principal Investigator/Program Director (Last, First, Middle):

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE
Joffre Baker, Ph.D	Chief Scientific Officer
eRA COMMONS USER NAME	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
University of California, San Diego	BA	1971	Biology and Chemistry
University of Hawaii	Ph.D	1977	Biochemistry

A. Professional Experience:

1/1977 – 12/1979	Postdoctoral Fellow, Department of Medical Microbiology, University of California, Irvine
1/1977 – 12/1979	Assistant Professor, Department of Biochemistry, University of Kansas
6/1984 – 6/1988	Associate Professor, Department of Biochemistry, University of Kansas
6/1988 – 9/1990	Senior Scientist, Department of Cardiovascular Research, Genentech, Inc.,
9/1990 – 7/1991	Acting Director, Department of Cardiovascular Research, Genentech, Inc.
7/1991 – 10/1993	Director, Department of Cardiovascular Research, Genentech, Inc.
3/1993 – 2/1997	Senior Director, Research Discovery, Genentech, Inc
2/1997 - 11/2000	Vice President, Research Discovery, Genentech, Inc.
11/2000 – Present	Chief Scientific Officer, Genomic Health, Inc.

Professional Societies:
American Society for Cell Biology and American Society for Biochemistry and Molecular Biology

Awards:
7/1983 – 7/1988: NIH Research Center Development Award

B. Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in preparation.

1. Baker JB, Humphreys T. Serum-stimulated release of cell contacts and the initiation of growth in contact-inhibited chick fibroblasts. Proc Natl Acad Sci U S A. 1971 Sep;68(9):2161-4. No abstract available. PMID: 4943788 [PubMed - indexed for MEDLINE]
2. Baker JB, Humphreys T. Turnover of molecules which maintain the normal surfaces of contact-inhibited cells. Science. 1972 Feb 25;175(24):905-6. No abstract available.
   PMID: 5008607 [PubMed - indexed for MEDLINE]
3. Baker JB, Cunningham DD. Glucocorticoid-mediated alteration in growth factor binding and action: analysis of the binding change. J Supramol Struct. 1978;9(1):69-77.
   PMID: 215839 [PubMed - indexed for MEDLINE]
4. Baker JB, Barsh GS, Carney DH, Cunningham DD. Dexamethasone modulates binding and action of epidermal growth factor in serum-free cell culture. Proc Natl Acad Sci U S A. 1978 Apr;75(4):1882-6. No abstract available.
   PMID: 306107 [PubMed - indexed for MEDLINE]
5. Simmer RL, Baker JB, Cunningham DD. Direct linkage of thrombin to its cell surface receptors in different cell types.J Supramol Struct. 1979;12(2):245-57. PMID: 544938 [PubMed - indexed for MEDLINE]
6. Cunningham DD, Glenn KC, Baker JB, Simmer RL, Low DA. Mechanisms of thrombin-stimulated cell division. J Supramol Struct. 1979;11(2):259-67. No abstract available. PMID: 548651 [PubMed - indexed for MEDLINE]
7. Baker JB, Simmer RL, Glenn KC, Cunningham DD. Glucocorticoids enhance the mitogenic action of insulin in serum-free cultures of chick embryo cells.J Cell Physiol. 1979 Mar;98(3):561-70. No abstract available.
   PMID: 438300 [PubMed - indexed for MEDLINE]

8. Baker JB, Simmer RL, Glenn KC, Cunningham DD. Thrombin and epidermal growth factor become linked to cell surface receptors during mitogenic stimulation. Nature. 1979 Apr 19;278(5706):743-5. No abstract available. PMID: 219372 [PubMed - indexed for MEDLINE]
9. Baker JB, Low DA, Simmer RL, Cunningham DD. Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell. 1980 Aug;21(1):37-45. PMID: 6157479 [PubMed - indexed for MEDLINE]
10. Low, D.A., Cunningham, D.D., Scott, R.W. and Baker, J.B. (1981). Interactions of Serine Proteases with Human Fibroblasts: Regulation by Protease-Nexin, A Cellular Component with Similarities to Antithrombin III. In Receptor – Mediated Binding and Internalization of Toxins a
11. Low DA, Baker JB, Koonce WC, Cunningham DD. released protease-nexin regulates cellular binding, internalization, and degradation of serine proteases.Proc Natl Acad Sci U S A. 1981 Apr;78(4):2340-4. PMID: 7017731 [PubMed - indexed for MEDLINE]
12. Comens PG, Simmer RL, Baker JB. Direct linkage of 125I-EGF to cell surface receptors. A useful artifact of chloramine-T treatment. J Biol Chem. 1982 Jan 10;257(1):42-5. No abstract available. PMID: 6273440 [PubMed - indexed for MEDLINE]
13. Low DA, Scott RW, Baker JB, and Cunningham DD. Cells regulate their mitogenic response to thrombin through release of protease nexin. Nature. 1982 Jul 29;298(5873):476-8. PMID: 7088192 [PubMed - indexed for MEDLINE]
14. Baker JB, Low DA, Eaton DL, Cunningham DD. Thrombin-mediated mitogenesis: the role of secreted protease nexin. J Cell Physiol. 1982 Aug;112(2):291-7. No abstract available. PMID: 7119026 [PubMed - indexed for MEDLINE]
15. Scott RW, Eaton DL, Duran N, Baker JB. Regulation of extracellular plasminogen activator by human fibroblasts. The role of protease nexin. J Biol Chem. 1983 Apr 10;258(7):4397-403. PMID: 6339496 [PubMed - indexed for MEDLINE]
16. Eaton DL, Baker JB. Phorbol ester and mitogens stimulate human fibroblast secretions of plasmin-activatable plasminogen activator and protease nexin, an antiactivator/antiplasmin. J Cell Biol. 1983 Aug;97(2):323-8. PMID: 6224800 [PubMed - indexed for MEDLINE]
17. Scott RW, Baker JB. Purification of human protease nexin. J Biol Chem. 1983 Sep 10;258(17):10439-44. PMID: 6885787 [PubMed - indexed for MEDLINE]
18. Eaton DL, Baker JB. Evidence that a variety of cultured cells secrete protease nexin and produce a distinct cytoplasmic serine protease-binding factor.J Cell Physiol. 1983 Nov;117(2):175-82. PMID: 6579053 [PubMed - indexed for MEDLINE]
19. Eaton DL, Scott RW, Baker JB. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin.J Biol Chem. 1984 May 25;259(10):6241-7. PMID: 6373753 [PubMed - indexed for MEDLINE]
20. Scott RW, Bergman BL, Bajpai A, Hersh RT, Rodriguez H, Jones BN, Barreda C, Watts S, Baker JB. Protease nexin. Properties and a modified purification procedure. J Biol Chem. 1985 Jun 10;260(11):7029-34. PMID: 3997857 [PubMed - indexed for MEDLINE]
21. Bajpai A, Baker JB. Cryptic urokinase binding sites on human foreskin fibroblasts. Biochem Biophys Res Commun. 1985 Dec 17;133(2):475-82. PMID: 3002345 [PubMed - indexed for MEDLINE]
22. Bajpai A, Baker JB. Urokinase binding sites on human foreskin cells. Evidence for occupancy with endogenous urokinase. Biochem Biophys Res Commun. 1985 Dec 31;133(3):994-1000. PMID: 3002380 [PubMed - indexed for MEDLINE]
23. Baker, J.B., Knauer, D.J. and Cunningham, D.D. (1986). Protease Nexins: Secreted Protease Inhibitors that Regulate Protease Action at and Near the Cell Surface. In The Receptors. Vol. 3. P.M. Conn, ed. Academic Press. Pp. 153-172
24. Gronke RS, Curry TK, Baker JB. Formation of protease nexin-thrombin complexes on the platelet surface. J Cell Biochem. 1986;32(3):201-6. PMID: 3782314 [PubMed - indexed for MEDLINE]
25. Baker, J.B., McGrogan, M., Simonsen, C.C., Scott, R.W., Gronke, R.S. and Honeyman, A. (1987). "Structure and Properties of Protease Nexin I/Glial-Derived Neurite Promotion Factor." In The Pharmacology and Toxicology of Proteins. (J.L. Winkelhake and J.S. Holcenbert, eds.) Alan R. Liss, Inc., New York. pp. 307-323
26. McGrogan, M., Kennedy, J., Li, M.P., Hsu, C., Scott, R.W. and Baker, J.B. (1988). Molecular Cloning and Expression Two Forms of Protease Nexin I. Bio/Technology. 6: 172-177
27. Bergman BL, Scott RW, Bajpai A, Watts S, Baker JB. Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc Natl Acad Sci U S A. 1986 Feb;83(4):996-1000. PMID: 3513169 [PubMed - indexed for MEDLINE]
28. Laug, W.E., Aebersold, R., Jong A., Rideout, W., Bergman, B.L. and Baker, J.B. (1989). Isolation of Multiple Types of Plasminogen Activator Inhibitors from Vascular Smooth Muscle Cells. Thromb. Haemost. 61: 517-521.
29. Baker JB, Gronke RS. Protease nexins and cellular regulation.Semin Thromb Hemost. 1986 Jul;12(3):216-20. No abstract available. PMID: 3775388 [PubMed - indexed for MEDLINE]
30. Gronke RS, Bergman BL, Baker JB. Thrombin interaction with platelets. Influence of a platelet protease nexin. J Biol Chem. 1987 Mar 5;262(7):3030-6. PMID: 3102483 [PubMed - indexed for MEDLINE]

31. Van Nostrand WE, McKay LD, Baker JB, Cunningham DD. Functional and structural similarities between protease nexin I and C1 inhibitor. J Biol Chem. 1988 Mar 15;263(8):3979-83. PMID: 3279027 [PubMed - indexed for MEDLINE]
32. Hebert CA, Baker JB. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol. 1988 Apr;106(4):1241-7. PMID: 3129438 [PubMed - indexed for MEDLINE]
33. Gronke RS, Knauer DJ, Veeraraghavan S, Baker JB. A form of protease nexin I is expressed on the platelet surface during platelet activation. Blood. 1989 Feb;73(2):472-8. PMID: 2917187 [PubMed - indexed for MEDLINE]
34. Rao JS, Kahler CB, Baker JB, Festoff BW. Protease nexin I, a serpin, inhibits plasminogen-dependent degradation of muscle extracellular matrix.Muscle Nerve. 1989 Aug;12(8):640-6. Review. PMID: 2506447 [PubMed - indexed for MEDLINE]
35. Gimbrone, M.A. Jr., Obin, M.S., Brock, A.F., Luis, E.A., Hass, P.E., Herbert, C.A., Yip, Y.K., Leung, D.W., Lowe, D.G., Kohr, W.J., Darbone, W.C., Bechtol, K.B. and Baker, J.B. (1989). Endothelial Interleukin-8: A Novel Inhibitor of Leukocyte-Endothelial Interactions. Science 246: 1601-1602
36. Ramakrishnan V, Sinicropi DV, Dere R, Darbonne WC, Bechtol KB, Baker JB. Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers. J Biol Chem. 1990 Feb 15;265(5):2755-62. PMID: 2105933 [PubMed - indexed for MEDLINE
37. Rao JS, Baker JB, Morantz RA, Kimler B, Evans R, Festoff BW. Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin. Cancer Res. 1990 Aug 15;50(16):5039-44. PMID: 2116223 [PubMed - indexed for MEDLINE]
38. Hebert CA, Luscinskas FW, Kiely JM, Luis EA, Darbonne WC, Bennett GL, Liu CC, Obin MS, Gimbrone MA Jr, Baker JB. Endothelial and leukocyte forms of IL-8. Conversion by thrombin and interactions with neutrophils. J Immunol. 1990 Nov 1;145(9):3033-40. PMID: 2212672 [PubMed - indexed for MEDLINE]
39. Herbert, C.A. and Baker, J.B. (1990). Thrombin Disintegrates Cell Surface Focal Urokinase/Adhesion Plaques and Decreases Cell Extension. In "Serine Proteases and Their Serpin Inhibitors in the Nervous System". B.W. Festoff, ed. Plenum Press, N.Y. pp. 41-5
40. Hechtman DH, Cybulsky MI, Fuchs HJ, Baker JB, Gimbrone MA Jr. Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol. 1991 Aug 1;147(3):883-92. PMID: 1650387 [PubMed - indexed for MEDLINE]
41. Baker, J.B., Hidalgo, J.J. and Borchardt, R.T. (1991). "Intestinal Epithelial and Vascular Endothelial Barriers." In Peptide and Protein Drug Delivery: Fundamentals and Technology. (V.H.L. Lee, ed.) Marcel Dekker, N.Y. pp. 359-387
42. Darbonne WC, Rice GC, Mohler MA, Apple T, Hebert CA, Valente AJ, Baker JB. Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest. 1991 Oct;88(4):1362-9. PMID: 1918386 [PubMed - indexed for MEDLINE]
43. Hebert CA, Vitangcol RV, Baker JB. Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem. 1991 Oct 5;266(28):18989-94. PMID: 1918013 [PubMed - indexed for MEDLINE]
44. Van Zee KJ, Fischer E, Hawes AS, Hebert CA, Terrell TG, Baker JB, Lowry SF, Moldawer LL. Effects of intravenous IL-8 administration in nonhuman primates. J Immunol. 1992 Mar 15;148(6):1746-52. PMID: 1541815 [PubMed - indexed for MEDLINE]
45. Lokker NA, Mark MR, Luis EA, Bennett GL, Robbins KA, Baker JB, Godowski PJ. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 1992 Jul;11(7):2503-10. PMID: 1321034 [PubMed - indexed for MEDLINE]
46. Luscinskas FW, Kiely JM, Ding H, Obin MS, Hebert CA, Baker JB, Gimbrone MA Jr. In vitro inhibitory effect of IL-8 and other chemo attractants on neutrophil-endothelial adhesive interactions.J Immunol. 1992 Sep 15;149(6):2163-71. PMID: 1381398 [PubMed - indexed for MEDLINE]
47. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992 Oct;90(4):1296-301. PMID: 1357002 [PubMed - indexed for MEDLINE]
48. Hebert CA, Baker JB. Interleukin-8: a review.Cancer Invest. 1993;11(6):743-50. Review. No abstract available. PMID: 8221207 [PubMed - indexed for MEDLINE]
49. White EA, Baker JB, McGrogan M, Kitos PA. Protease nexin 1 is expressed in the human placenta. Thromb Haemost. 1993 Feb 1;69(2):119-23. PMID: 8456423 [PubMed - indexed for MEDLINE]
50. Morgenstern KA, Henzel WJ, Baker JB, Wong S, Pastuszyn A, Kisiel W. Isolation and Characterization of an Intracellular Serine Proteinase Inhibitor from Monkey Kidney epithelial Cell line. J. Biol Chem. 1993 Oct 15;268(29):21560-8. PMID: 8408007 [PubMed - indexed for MEDLINE
51. Ley K, Baker JB, Cybulsky MI, Gimbrone MA Jr, Luscinskas FW.

Intravenous interleukin-8 inhibits granulocyte emigration from rabbit mesenteric venules without altering L-selectin expression or leukocyte rolling. J Immunol. 1993 Dec 1;151(11):6347-57. PMID: 7504019 [PubMed - indexed for MEDLINE]

52. Jin H, Yang R, Marsters S, Ashkenazi A, Bunting S, Marra MN, Scott RW, Baker JB. Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J Clin Invest. 1995 Apr;95(4):1947-52. PMID: 7706502 [PubMed - indexed for MEDLINE]
53. Pennica, D., King, K.L., Shaw, K.J., Luis, E., Rullamas, J., Luoh, S.M., Darbonne, W.C., Knutzon, D.S., Yen, R., Chien, K.R., Baker, J.B., and Wood, W.I.. (1995). Cardiotrophin 1, A Cytokine that Induces Cardiac Myocyte Hypertrophy. Proc. Natl. Acad. Sci. USA, 92: 1142-114
54. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.Am J Pathol. 2004 Jan;164(1):35-42. PMID: 14695316 [PubMed - indexed for MEDLINE]
55. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 Dec 30;351(27):2817-26.
56. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S. (2005). Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005 Dec 15;11(24):8623-31.
57. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S. (2005)Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005 Oct 10;23(29):7265-77. Epub 2005 Sep 6
58. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8(3):R25. Epub 2006 May 31. PMID: 16737553 [PubMed - in process]
59. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006 Aug 10;24(23):3726-34. Epub 2006 May 23. PMID: 16720680 [PubMed - indexed for MEDLINE]

C. Research Support. List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and your role (e.g. PI, Co-Investigator, Consultant) in the research project. Do not list award amounts or percent effort in projects.